Sign In
Buy CELU
$1.06
-0.0100 (-0.93%)
At Close: Jun 02, 2026
5 Beaten-Down Biotech Bets to Bounce Back in 2022
03:18pm, Friday, 31'st Dec 2021
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Celularity Appoints Andrew L. Pecora, M.D.
08:00am, Wednesday, 15'th Sep 2021
Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25 years' experience developing life-changing cellular medicines Renowned clinician, scientist
Celularity: Celgene Spin-Off Developing Allogeneic Therapies
09:13am, Monday, 06'th Sep 2021
Celularity is developing off-the-shelf placenta-derived allogeneic cellular therapies that overcome the problem of donor-patient match. The company was spun out from Celgene in 2016-2017.
Celularity Reports Second Quarter 2021 Financial Results
05:15pm, Monday, 16'th Aug 2021
FLORHAM PARK, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic the
Imugene details the fine print on Celularity partnership
01:59am, Tuesday, 10'th Aug 2021
Imugene Limited has provided additional information on a recent partnership with NASDAQ-listed biotech Celurlarity Inc. The clinical-stage immune-oncology company told the local share market it had pa
Imugene enters into strategic partnership with Celularity to develop immunotherapy for solid tumors
10:21pm, Wednesday, 04'th Aug 2021
Imugene Ltd has entered into a research collaboration with Celurlarity Inc to develop a novel oncolytic virus allogeneic CAR T-Cell immunotherapy combination for the treatment of solid tumors. As part
SYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company and Celularity Inc. (“Celularity”) (Nas
Celularity Closes Merger With GX Acquisition (GXGX)
01:15pm, Friday, 16'th Jul 2021
Celularity announced it closed a merger with GX Acquisition Corp (NASDAQ: GXGX) and provided a corporate update. These are the details.
Celularity Closes SPAC Merger With GX Acquisition, Trading Starts Monday
12:27pm, Friday, 16'th Jul 2021
Celularity Inc has closed the merger with GX Acquisition Corp (NASDAQ: GXGX), giving Celularity $138 million to push the NK cell and T cell therapies into early-stage trials. The combined company w
